Company profile: ITS Innovation
1.1 - Company Overview
Company description
- Provider of synthetic vaccines for mutating viruses using a T-cell vaccine platform that targets conserved viral antigens to direct immune responses, and of pemvidutide, a GLP-1/glucagon dual receptor agonist for obesity and MASH, designed to reduce body weight, liver fat, serum lipids, and address liver fat and fibrosis.
Products and services
- Pemvidutide for MASH: A custom-engineered GLP-1/glucagon dual-receptor agonist targeting metabolic dysfunction-associated steatohepatitis by addressing liver fat and fibrosis
- Pemvidutide for Obesity: A dual-receptor GLP-1/glucagon agonist developed to treat obesity by reducing body weight, liver fat content, and serum lipids
- T-cell Vaccine Platform: A synthetic, enabling platform that targets highly conserved viral antigens and directs T-cell immune responses to cells infected by mutating, difficult viruses
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ITS Innovation
ISR Immune System Regulation
HQ: Sweden
Website
- Description: Provider of innovation-driven immunotherapy research, conducting preclinical and clinical studies to develop novel drugs for curative treatment of viral infections, based at the Karolinska Hospital in Stockholm, Sweden.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ISR Immune System Regulation company profile →
Lumen Bioscience
HQ: United States
Website
- Description: Provider of biologic drug and vaccine development and manufacturing, leveraging a platform for rapid, cost-effective production. Pipeline includes biologic cocktails for C. difficile colitis, Covid-19 GI infection, and inflammatory bowel disease, a preclinical cardiometabolic program with Novo Nordisk, and a Phase 2 product candidate for traveler’s diarrhea backed by CARB-X and the Bill & Melinda Gates Foundation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lumen Bioscience company profile →
Atriva Therapeutics
HQ: Germany
Website
- Description: Provider of host-targeting antiviral therapies for respiratory viral infections. Its lead candidate, zapnometinib (ATR-002), is an orally available small molecule designed to inhibit viral replication and modulate immune response to treat severe RNA-virus infections. Completed a Phase I safety study; assessing efficacy and safety in a Phase II study in hospitalized severe COVID-19 and planning Phase II development for severe influenza.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Atriva Therapeutics company profile →
Inositec
HQ: Switzerland
Website
- Description: Provider of treatments for soft tissue calcification disorders based on its proprietary Inositune platform of inositol phosphate (IP6) analogs, with lead programs targeting vascular and renal calcification, including orphan indications; founded in 2015 as a spin-off of ETH Zurich.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inositec company profile →
MedMira
HQ: Canada
Website
- Description: Provider of rapid diagnostics, including FDA-approved Reveal G4 for instant HIV results using Rapid Vertical Flow Technology; Multiplo Multiplex Tests for simultaneous detection of HIV-1/2, hepatitis B and C, and syphilis; Reveal HIV; Multiplo TP/HIV; Multiplo HBc/HIV/HCV; and the Miriad RVF Toolkit for developing and commercializing rapid tests.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MedMira company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ITS Innovation
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ITS Innovation
2.2 - Growth funds investing in similar companies to ITS Innovation
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ITS Innovation
4.2 - Public trading comparable groups for ITS Innovation
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →